Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1897 - Reproductive function in patients (pts) with malignant ovarian germ cell tumors (MOGCT) following chemotherapy (ChT)


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Ovarian Cancer


Dzhennet Chekini


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


D. Chekini1, A. Tryakin1, M. Fedyanin1, I. Pokataev1, A. Bulanov1, T. Zakharova2, K. Zhordania3, O. Sekhina1, S. Tjulandin1

Author affiliations

  • 1 Clinical Pharmacology And Chemotherapy Department, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2 Pathology, Russian Oncology Research Center named after Blokhin N.N., 115478 - Moscow/RU
  • 3 Gynecology Department, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU


Abstract 1897


MOGCT generally affect young women, grow rapidly, usually involve one ovary and are highly chemosensitive. Only a few studies have evaluated the reproductive outcomes of pts following ChT. The aim of this study was analysis of long-term effects of ChT on reproductive function in a large population of young women treated for MOGCT in our center.


Inclusion criteria in our study were MOGCT, fertility-sparing surgery, cisplatin- and etoposide-based induction ChT (BEP/EP regimen), age under 40, no relapse following ChT at least 1 year. Blood tests were taken for hormones of ovarian function (follicle-stimulating hormone, luteinizing hormone, estradiol, anti-Müllerian hormone (AMH), inhibin B) to assess their menstrual, reproductive function, post therapeutic status of pregnancy or delivery.


A total of 47/163 (28.8%) pts with MOGCT treated in our center between 1987-2015 satisfied to the criteria. Mean age was 21 years (range, 14-35). Median number of ChT cycles was 4 (range, 1-6). The 5-year OS was 85% for all pts and 100% for these 47 women. All pts recovered their menstrual function during the first year after completion of ChT. With median f.-up 90 mo. (range, 12-228), 23/47 (49%) pts attempted conception, 18/23 (78.3%) women conceived with 20 live birth deliveries. There were 2/18 (11%) miscarriages and 6/18 (33.3%) terminations. Four women were pregnant at the moment of the analysis. Inhibin B level was normal in all 15 evaluated pts (median 74,4 pg/ml, range 10-120). Median of AMH level was 0,97 ng/ml (range 0.08-6). In 10 (52.6%) of 19 pts AMH level was


Unilateral adnexectomy followed by modern cisplatin-based chemotherapy does not adversely affect young women’s fertility and provides high chance for cure.

Clinical trial identification

Legal entity responsible for the study

Russian Cancer Research Center




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.